Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.66 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.66 |
| ▸ | SHBG | P04278 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7905737 | 1.00 | SRD5A2 (0.66) | SRD5A2SRD5A1SHBGCYP3A4CYP19A1 | |
| SCHEMBL8986784 | 1.00 | SRD5A2 (0.66) | SRD5A2SRD5A1SHBGCYP3A4CYP19A1 | |
| SCHEMBL8680322 | 0.84 | SRD5A2 (0.75) | SRD5A2SRD5A1 | |
| SCHEMBL7384872 | 0.83 | SRD5A1 (0.62) | SRD5A2SRD5A1SHBGCYP3A4CYP19A1 | |
| SCHEMBL8680318 | 0.82 | SRD5A1 (0.61) | SRD5A2SRD5A1SHBGCYP3A4 | |
| SCHEMBL8590259 | 0.81 | SRD5A2 (0.68) | SRD5A2SRD5A1 | |
| SCHEMBL917612 | 0.80 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| SCHEMBL8333868 | 0.80 | SRD5A2 (1.00) | SRD5A2SRD5A1 | |
| SCHEMBL7613573 | 0.79 | SRD5A1 (0.67) | SRD5A1SHBGCYP3A4CYP19A1LMNA | |
| SCHEMBL7613570 | 0.79 | SRD5A1 (0.67) | SRD5A1SHBGCYP3A4CYP19A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0778284-A2 | New 7-beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1997-06-11 | — | — | EP | claimed |
| EP-0572166-A1 | New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | claimed |
| JP-6100587-A | — | — | None | — | — | JP | disclosed |
| US-6204273-B1 | TREATMENT OF ANDROGENIC SENSITIVE DISORDERS SUCH AS ACNE VULGARIS, SEBORRHEA, FEMALE HIRSUTISM, MALE PATTERN BALDNESS, AND BENIGN PROSTATIC HYPERPLASIA. | MERCK & CO., INC. | 2001-03-20 | — | — | US | disclosed |
| EP-0756481-B1 | 17$g(b)-ARYL-4-AZA-STEROID DERIVATIVES | MERCK & CO INC (US) | 2000-12-27 | — | — | EP | disclosed |
| US-5910497-A | 16-pyrazinyl-substituted-4-aza-androstane 5-α-reductase isozyme 1 inhibitors | MERCK & CO., INC. (US) | 1999-06-08 | — | — | US | disclosed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0724592-B1 | 16-SUBSTITUTED-4-AZA-ANDROSTANE 5-ALPHA-REDUCTASE ISOZYME 1 INHIBITORS | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0756481-A4 | 17-g(b)-ARYL-4-AZA-STEROID DERIVATIVES | MERCK & CO INC (US) | 1998-11-18 | — | — | EP | disclosed |
| EP-0700291-B1 | 15-SUBSTITUTED 4-AZASTEROIDS | MERCK & CO INC (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0700291-A1 | 15-SUBSTITUTED 4-AZASTEROIDS | MERCK & CO. INC. (US) | 1996-03-13 | — | — | EP | disclosed |
| WO-1995028928-A1 | 17β-ARYL-4-AZA-STEROID DERIVATIVES | MERCK & CO., INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| WO-1995011254-A1 | 16-SUBSTITUTED-4-AZA-ANDROSTANE 5-ALPHA-REDUCTASE ISOZYME 1 INHIBITORS | MERCK & CO., INC. (US) | 1995-04-27 | — | — | WO | disclosed |
| US-5359071-A | Selective antagonist of testosterone 5-alpha-reductase 1 | MERCK & CO., INC. (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994020104-A1 | 15-SUBSTITUTED 4-AZASTEROIDS | MERCK & CO, INC. (US) | 1994-09-15 | — | — | WO | disclosed |
| JP-H06100587-A | NEW 7 BETA-SUBSTITUTED-4-AZA-5-ALPHA-ANDROSTAN-3-ONE AS 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO INC | 1994-04-12 | — | — | JP | disclosed |
| EP-0572166-A1 | New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | disclosed |